Discovery MPACs

About Alterity Therapeutics

Alterity Therapeutics is dedicated to creating disease-modifying treatments for debilitating neurodegenerative disorders, with a core focus on Parkinsonian conditions. The company's technology platform centers on metal protein attenuating compounds (MPACs) that aim to reduce the toxic accumulation of misfolded proteins in the brain. Its lead asset, ATH434, is currently in Phase 2 clinical trials, representing a potentially novel therapeutic approach for diseases with high unmet medical need. As a publicly listed entity, Alterity is advancing its pipeline through strategic clinical development to generate critical proof-of-concept data.

Therapeutic Areas